Abstract
Although recent in vitro studies have begun to decipher the molecular events that characterize the anergic state, their in vivo biologic relevance and potential clinical importance remain unclear. Here, using anergic human T-cell clones and tolerant alloreactive mouse T cells that do not induce graft-versus-host disease, we show that p27kip1 cyclin-dependent kinase inhibitor is an essential regulator responsible for the blockade of clonal expansion of anergic T cells in vitro and in vivo. Moreover, in anergic cells, p27kip1 associates with the c-Jun co-activator JAB1, resulting in defective transactivation of AP-1 and interleukin 2 transcription. Therefore, pharmacological agents that upregulate the expression of or prevent the degradation of p27kip1 during antigen recognition should be part of new therapeutic strategies to induce antigen-specific T-cell unresponsiveness.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Schwartz, R.H. T-cell clonal anergy. Curr. Opin. Immunol. 9, 351–357 (1997).
Larsen, C.P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).
Kirk, A.D. et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. 94, 8789–8794 (1997).
Blazar, B.R., Taylor, P.A., Linsley, P.S. & Vallera, P.A. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83, 3815–3825 (1994).
Blazar, B.R., Taylor, P., Noelle, R.J. & Vallera, D.A. CD4+ T-cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host lethality capacity but retain normal antigen responses. J.Clin. Invest. 102, 473–482 (1998).
Guinan, E.C. et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704–1714 (1999).
Cho, E.A., Riley, M.P., Sillman, A.L. & Quill, H. Altered protein tyrosine phosphorylation in anergic Th1 cells. J. Immunol. 151, 20–28 (1993).
Madrenas, J. et al. ζ phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 267, 515–518 (1994).
Boussiotis, V.A. et al. Differential association of protein tyrosine kinases with T-cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J. Exp. Med. 184, 365–376 (1996).
Fields, P.E., Gajewski, T.F. & Fitch, F.W. Blocked Ras activation in anergic CD4+ T-cells. Science 271, 1276–1278 (1996).
Kang, S.M. et al. Transactivation by AP-1 is a molecular target of T-cell clonal anergy. Science 257, 1134–1138 (1992).
Mondino, A. et al. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB and JunB in anergic T helper 1 cells. J. Immunol. 157, 2048–2057 (1996).
Quill, H. et al. Anergic Th1 cells express altered levels of the protein tyrosine kinases p56lck and p59fyn. J. Immunol. 149, 2887–2893 (1992).
Gajewski, T.F., Qian, D., Fields, P. & Fitch, F.W. Anergic T-lymphocyte clones have altered inositol phosphate, calcium and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA 91, 38–42 (1994).
Gajewski, T.F., Fields, P. & Fitch, F.W. Induction of the increased fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur. J. Immunol. 25, 1836–1842 (1995).
Sloan-Lancaster, J., Steinberg, T.H. & Allen, P.M. Selective activation of the calcium signaling pathway by altered peptide ligands. J. Exp. Med. 184, 1525–1530 (1996).
Boussiotis, V.A., Freeman, G.J., Berezovskaya, A., Barber, D.L. & Nadler, L.M. Maintenance of human T-cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science 278, 124–128 (1997).
Beverly, B., Kang, S.M., Lenardo, M.J. & Schwartz, R.H. Reversal of in vitro T-cell clonal anergy by IL-2 stimulation. Int. Immunol. 4, 661–671 (1992).
Gilbert, K.M. & Weigle, W.O. Th1 cell anergy and blockade in G1a phase of the cell cycle. J. Immunol. 151, 1245–1254 (1993).
DeCaprio, J.A., Furukawa, T., Ajchenbaum, F., Griffin, J.D. & Livingston, D.M. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl.Acad. Sci. USA 89, 1795–1798 (1992).
Sherr, C.J. & Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149–1163 (1995).
Vlach, J., Hennecke, S. & Amati, B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27kip1. EMBO J. 17, 5334–5344 (1997).
Ajchenbaum, F., Ando, K., DeCaprio, J.A. & Griffin, J.D. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J. Biol. Chem. 268, 4113–4119 (1993).
Kwon, T.K., Buchholz, M.A., Ponsalle, P., Chrest, F.J. & Nordin, A.A. The regulation of p27kip1 expression following the polyclonal activation of murine Go T-cells. J. Immunol. 158, 5642–5648 (1997).
Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/cdk4. Nature 366, 704–704 (1993).
Chan, F.K., Zhang, J., Cheng, L., Shapiro, D.N. & Winoto, A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol. Cell. Biol. 15, 2682–2688 (1995).
Polyak, K. et al. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59–66 (1994).
Kamesaki, H.K.N., Michaud, G.Y., Cossamn, J. & Kiyono, T. TGF-β induces the cyclin-dependent kinase inhibitor p27kip1 mRNA and protein in murine B cells. J. Immunol. 160, 770–777 (1998).
Kato, J., Matsuoka, M., Polyak, K., Massague, J. & S.J., C. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27kip1) of cyclin-dependent kinase 4 activation. Cell 79, 487–496 (1994).
Elliot, G. & O'Hare, P. Intercellular trafficking and protein delivery by a herpervirus structural protein. Cell 88, 223–233 (1997).
Waga, S., Hannon, G.J., Beach, D. & Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574–578 (1994).
Nourse, J. et al. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372, 570–573 (1994).
Tomoda, K., Kubota, Y. & Kato, J. Degradation of the cyclin-dependent-kinase inhibitor p27kip1 is instigated by Jab1. Nature 398, 160–165 (1999).
Claret, F.X., Hibi, M., Dhut, S., Toda, T. & Karin, M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383, 453–457 (1996).
Grewal, I.J. & Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111–135 (1998).
Tamir, A., Granot, Y. & Isakov, N. Inhibition of T lymphocyte activation by cAMP is associated with downregulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J. Immunol. 157, 1514–1522 (1996).
Li, L., Yee, C. & Beavo, J.A. CD3- and CD28-dependent induction of PDE7 required for T-cell activation. Science 283, 848–851 (1999).
de Rooij, J. et al. Epac is a Rap1 guanidine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396, 474–477 (1998).
Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. & Noda, M. A ras-related gene with transformation suppressor activity. Cell 56, 77–84 (1989).
Kawada, M. et al. Induction of p27kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15, 629–237 (1997).
Nunes, J.A., Collette, Y., Truneh, A., Olive, D. & Cantrell, D.A. The role of p21ras in CD28 signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras. J. Exp. Med. 180, 1067–1076 (1994).
Powell, J.D., Lerner, C.G. & Schwartz, R.H. Inhibition of cell cycle progression by rapamycin induces T-cell clonal anergy even in the presence of costimulation. J. Immunol. 162, 2775–2784 (1999).
Li, Y., Zheng, X.X., Li, X.C., Zand, M.S. & Strom, T.B. Combined costimulation blockade plus rapamycin but not cyclosporin produces permanent engraftment. Transplantation 66, 1387–1388 (1998).
Granger, D. et al. Prolonged survival without posttransplant immunosuppression in a large animal model. Surgery 116, 236–241 (1994).
Matsushime, H. et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066–2076 (1994).
Acknowledgements
This study was supported by National Institutes of Health grants AI 43552, AI 41584, HL 54785, AI 34495 and HL 56067, and a research grant from the National Marrow Donor Program.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boussiotis, V., Freeman, G., Taylor, P. et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 6, 290–297 (2000). https://doi.org/10.1038/73144
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/73144
This article is cited by
-
Immunomodulation by anticancer cell cycle inhibitors
Nature Reviews Immunology (2020)
-
MicroRNA-150 modulates intracellular Ca 2+ levels in naïve CD8+ T cells by targeting TMEM20
Scientific Reports (2017)
-
The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity
Nature Communications (2016)
-
JAB1 is Involved in Neuropathic Pain by Regulating JNK and NF-κB Activation After Chronic Constriction Injury
Neurochemical Research (2016)
-
New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation
Nature Reviews Immunology (2014)